UB Paderborn / Katalog / Suche / in CDI

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America

The Journal of infectious diseases, 2016-10, Vol.214 (7), p.994-1000

2016

Volltextzugriff (PDF)

Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study

The Lancet infectious diseases, 2022-06, Vol.22 (6), p.901-911

2022

Volltextzugriff (PDF)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018-04, Vol.112 (4), p.158-168

2018

Volltextzugriff (PDF)

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants Across a Broad Age Range (2–55 years) in Japan: A Phase III Randomized Study

Japanese Journal of Infectious Diseases, 2023/01/31, pp.JJID.2022.272

2023

Volltextzugriff (PDF)

Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response

The American journal of tropical medicine and hygiene, 2019-01, Vol.101 (1), p.164-179

2019

Volltextzugriff (PDF)

Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America

The American journal of tropical medicine and hygiene, 2021-01, Vol.104 (1), p.136-144

2021

Volltextzugriff (PDF)

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America

The Pediatric infectious disease journal, 2013-10, Vol.32 (10), p.1102-1109

2013

Volltextzugriff (PDF)

Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru: A Randomized Trial

The Pediatric infectious disease journal, 2016-10, Vol.35 (10), p.1140-1147

2016

Volltextzugriff (PDF)

Immunogenicity and Safety of an Investigational Hexavalent Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus-hepatitis B-Haemophilus influenzae B Conjugate Combined Vaccine in Healthy 2-, 4-, and 6-month-old Argentinean Infants

The Pediatric infectious disease journal, 2011-06, Vol.30 (6), p.e88-e96

2011

Volltextzugriff (PDF)

Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule

The Pediatric infectious disease journal, 2019-05, Vol.38 (5), p.e90

2019

Volltextzugriff (PDF)

Immunogenicity and safety of a novel yeast Hansenula polymorpha -derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years

Vaccine, 2010-04, Vol.28 (20), p.3595-3601

2010

Volltextzugriff (PDF)

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S125-S125

2021

Volltextzugriff (PDF)

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S125-S126

2021

Volltextzugriff (PDF)

Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America

The American journal of tropical medicine and hygiene, 2015-07, Vol.93 (1), p.18-23

2015

Volltextzugriff (PDF)

Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America

The Pediatric infectious disease journal, 2012-08, Vol.31 (8), p.e126-e132

2012

Volltextzugriff (PDF)

A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

Vaccine, 2012-10, Vol.30 (45), p.6492-6500

2012

Volltextzugriff (PDF)

Epidemiology of Dengue in Latin America

Journal of the Pediatric Infectious Diseases Society, 2014-09, Vol.3 (3), p.181-182

2014

Volltextzugriff (PDF)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico

Human vaccines & immunotherapeutics, 2014-10, Vol.10 (10), p.2853-2863

2014

Volltextzugriff (PDF)

Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9―16 Year Olds: A Randomized, Controlled, Phase,∥ Trial in Latin America

The Pediatric infectious disease journal, 2013, Vol.32 (10), p.1102-1109

2013

Volltextzugriff (PDF)

Consideraciones generales sobre el mercurio, el timerosal, y su uso en vacunas pediátricas

Revista médica del Uruguay, 2004-03, Vol.20 (1)

Betzana Zambrano

2004

Volltextzugriff (PDF)

Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies

Vaccine, 2003-09, Vol.21 (25-26), p.3730-3733

2003

Volltextzugriff (PDF)

Estado actual de las vacunas contra el Dengue: perspectivas

Revista biomédica, 2010, Vol.21 (3), p.197-211

Zambrano Mora, Betzana M

2010

Volltextzugriff (PDF)

Consideraciones generales sobre el mercurio, el timerosal, y su uso en vacunas pediátricas

Revista Médica del Uruguay, 2004-03, Vol.20 (1), p.4-11

Zambrano, Betzana

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America

Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants Across a Broad Age Range (2–55 years) in Japan: A Phase III Randomized Study

Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response

Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America

Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru: A Randomized Trial

Immunogenicity and Safety of an Investigational Hexavalent Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus-hepatitis B-Haemophilus influenzae B Conjugate Combined Vaccine in Healthy 2-, 4-, and 6-month-old Argentinean Infants

Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule

Immunogenicity and safety of a novel yeast Hansenula polymorpha -derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan

Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America

Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America

A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

Epidemiology of Dengue in Latin America

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico

Analysis of hospitalized and severe dengue cases over the six-years of follow-up of the tetravalent dengue vaccine (CYD-TDV) efficacy trials in Asia and Latin America

Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9―16 Year Olds: A Randomized, Controlled, Phase,∥ Trial in Latin America

Consideraciones generales sobre el mercurio, el timerosal, y su uso en vacunas pediátricas

Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies

Estado actual de las vacunas contra el Dengue: perspectivas

Consideraciones generales sobre el mercurio, el timerosal, y su uso en vacunas pediátricas

Suchergebnisse filtern